Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVO Evotec	$4.73 +17.4%	$3.72	$2.84 ▼ $5.64	$1.68B	1.71	131,882 shs	530,776 shs
GPCR Structure Therapeutics	$24.55 -0.4%	$21.53	$13.22 ▼ $62.74	$1.41B	-1.69	932,263 shs	267,802 shs
JANX Janux Therapeutics	$25.22 +0.0%	$28.03	$22.48 ▼ $71.71	$1.49B	3.24	874,124 shs	1.18 million shs
URGN UroGen Pharma	$4.19 +2.7%	$10.03	$3.42 ▼ $20.70	$193.19M	0.66	672,612 shs	2.33 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVO Evotec	0.00%	+16.50%	+12.35%	+6.53%	-8.51%
GPCR Structure Therapeutics	0.00%	-2.46%	+3.81%	+3.61%	-32.52%
JANX Janux Therapeutics	0.00%	+3.87%	-21.36%	-29.96%	-44.39%
URGN UroGen Pharma	0.00%	-42.68%	-58.56%	-58.43%	-68.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVO Evotec	1.4252 of 5 stars	3.2	2.0	0.0	2.1	0.0	0.6
GPCR Structure Therapeutics	2.0066 of 5 stars	3.5	1.0	0.0	2.8	1.7	0.6
JANX Janux Therapeutics	2.7473 of 5 stars	3.5	0.0	0.0	4.2	5.0	0.0
URGN UroGen Pharma	3.9832 of 5 stars	4.4	1.0	4.5	2.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVO Evotec	2.40	Hold	$5.93	25.44% Upside
GPCR Structure Therapeutics	3.00	Buy	$79.86	225.28% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	277.68% Upside
URGN UroGen Pharma	2.88	Moderate Buy	$27.43	554.62% Upside

Current Analyst Ratings Breakdown

Latest URGN, GPCR, JANX, and EVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN UroGen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/22/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/15/2025	EVO Evotec	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/13/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/8/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/29/2025	URGN UroGen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	URGN UroGen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
4/28/2025	URGN UroGen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVO Evotec	$788.22M	2.13	$0.03 per share	161.08	$3.42 per share	1.38
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
JANX Janux Therapeutics	$9.34M	159.85	N/A	N/A	$7.46 per share	3.38
URGN UroGen Pharma	$91.87M	2.10	N/A	N/A	($2.78) per share	-1.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVO Evotec	-$90.82M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/13/2025 (Estimated)
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	N/A
JANX Janux Therapeutics	-$58.29M	-$1.36	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	8/6/2025 (Estimated)
URGN UroGen Pharma	-$102.24M	-$3.18	N/A	N/A	N/A	-129.11%	N/A	-47.94%	8/12/2025 (Estimated)

Latest URGN, GPCR, JANX, and EVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	URGN UroGen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
3/10/2025	Q4 2024	URGN UroGen Pharma	-$0.69	-$0.80	-$0.11	-$0.80	$25.25 million	$24.57 million
2/27/2025	Q4 2024	GPCR Structure Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	N/A	N/A
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVO Evotec	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN UroGen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVO Evotec	0.43	2.09	1.99
GPCR Structure Therapeutics	N/A	27.63	27.63
JANX Janux Therapeutics	N/A	38.80	38.80
URGN UroGen Pharma	4.77	9.00	8.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVO Evotec	5.81%
GPCR Structure Therapeutics	91.78%
JANX Janux Therapeutics	75.39%
URGN UroGen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
EVO Evotec	1.00%
GPCR Structure Therapeutics	9.43%
JANX Janux Therapeutics	29.40%
URGN UroGen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVO Evotec	4,200	355.11 million	350.83 million	Not Optionable
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
JANX Janux Therapeutics	30	59.18 million	37.05 million	Optionable
URGN UroGen Pharma	200	46.11 million	22.26 million	Optionable

URGN, GPCR, JANX, and EVO Headlines

Recent News About These Companies

Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky Investigates

May 25 at 5:33 AM | markets.businessinsider.com

UroGen Pharma (NASDAQ:URGN) Rating Lowered to "Neutral" at HC Wainwright

May 25 at 2:11 AM | americanbankingnews.com

Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky Investigates

May 24 at 6:01 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman

May 24 at 4:19 PM | morningstar.com

UroGen Pharma (NASDAQ:URGN) Price Target Cut to $3.00 by Analysts at The Goldman Sachs Group

May 24 at 10:49 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

May 24 at 9:00 AM | accessnewswire.com

HC Wainwright Reiterates "Neutral" Rating for UroGen Pharma (NASDAQ:URGN)

May 24 at 8:10 AM | marketbeat.com

Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN)

May 23 at 3:41 PM | theglobeandmail.com

Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky

May 23 at 1:00 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman

May 23 at 12:30 PM | accessnewswire.com

HC Wainwright & Co. Downgrades UroGen Pharma (URGN)

May 23 at 10:40 AM | msn.com

Potential Securities Fraud: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN)

May 23 at 10:15 AM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23 at 10:00 AM | accessnewswire.com

Point72 Asset Management L.P. Sells 1,189,532 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

May 23 at 4:36 AM | marketbeat.com

URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now

May 22 at 5:15 PM | accessnewswire.com

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny â€“ Hagens Berman

May 22 at 5:04 PM | globenewswire.com

UroGen tanks as FDA panel vote goes against UGN-102

May 22 at 2:03 PM | thepharmaletter.com

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Investigation

May 22 at 10:30 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the Investigation

May 22 at 10:00 AM | accessnewswire.com

1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion Bank

May 22 at 5:05 AM | marketbeat.com

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

May 21, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, GPCR, JANX, and EVO Company Descriptions

Evotec NASDAQ:EVO

$4.73 +0.70 (+17.37%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.72 -0.01 (-0.11%)

As of 05/23/2025 07:59 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Structure Therapeutics NASDAQ:GPCR

$24.55 -0.10 (-0.41%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$24.12 -0.44 (-1.77%)

As of 05/23/2025 07:12 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Janux Therapeutics NASDAQ:JANX

$25.22 +0.01 (+0.04%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$25.16 -0.06 (-0.24%)

As of 05/23/2025 06:44 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

UroGen Pharma NASDAQ:URGN

$4.19 +0.11 (+2.70%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$4.16 -0.04 (-0.84%)

As of 05/23/2025 07:59 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time